Product Information
SUMATRIPTAN SUCC 100 MG TABLET is a generic product labeled by Bionpharma Inc., priced at $0.4388 per EA under NDC 69452034672. Its NADAC has been published 221 times since Jul 13, 2022.
FDA first approved this application on Aug 10, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Sumatriptan market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
100 mg/1
Manufacturer
Bionpharma Inc.NDC
69452034672
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTAN SUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA078284FDA Approved
8/10/2009
TE Code
AB
On Market Since
2/18/2022
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN SUCC 100 MG TABLET has been published 221 times since Jul 13, 2022, and over the history we have for it it has declined 16.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4388 per EA |
|---|---|
| All-time high | $0.5292 (Oct 12, 2022) |
| All-time low | $0.3720 (Nov 20, 2024) |
| 52-week high | $0.4721 |
| 52-week low | $0.4309 |
| Median price | $0.4667 |
| Average price | $0.4639 |
| Largest weekly change | -23.3% (Nov 20, 2024) |
| Weeks tracked | 221 |
| Tracking since | Jul 13, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 7% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bionpharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sumatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN SUCC 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN SUCC 100 MG TABLET, manufactured by Bionpharma Inc., is $0.4388 per EA (NDC 69452034672), effective Sep 30, 2026.
How has the price of SUMATRIPTAN SUCC 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN SUCC 100 MG TABLET has declined 16.5%. It has been tracked across 221 weekly CMS publications since Jul 13, 2022.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN SUCC 100 MG TABLET?
Since Jul 13, 2022, the NADAC for SUMATRIPTAN SUCC 100 MG TABLET has ranged from a low of $0.3720 (Nov 20, 2024) to a high of $0.5292 (Oct 12, 2022), with a median of $0.4667 per EA.
Are there cheaper alternatives to SUMATRIPTAN SUCC 100 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SUMATRIPTAN SUCC 100 MG TABLET, is $0.4082 per EA — about 7% below SUMATRIPTAN SUCC 100 MG TABLET.
Who manufactures SUMATRIPTAN SUCC 100 MG TABLET?
SUMATRIPTAN SUCC 100 MG TABLET (NDC 69452034672) is labeled by Bionpharma Inc., and CMS classifies it as a generic product.